A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Collaborative
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Objective To identify the attitudes of German thyroid specialists towards the clinical treatment of hypothyroidism using thyroid hormones (TH). Methods All members of the thyroid section of the German Endocrine Society (DGE) were e-mailed an invitation to participate in a web-based survey about substitution with TH. Results Out of 206 members of the DGE’s thyroid section, 163 (79.1%) responses were received and included in the analysis. Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed combination therapy with liothyronine (LT4+LT3) in their clinical practice (p<0.001). LT4+LT3 combination was favored in patients with persistent hypothyroidism symptoms despite biochemical euthyroidism on LT4 treatment (p<0.001). Of all respondents, 26.4% never indicated TH therapy for euthyroid patients (p<0.001), while the remainder would consider THs for one or more indications (62.9% for euthyroid infertile women with high anti-thyroid antibody levels (p<0.001), 7.1% in patients with severe hypercholesterolemia, as complementary treatment (p=0.007), and 57.1% in patients with simple goiter (p<0.001)). In conditions that could interfere with LT4 absorption, most respondents still preferred tablets and did not expect a significant difference when switching from one LT4 formulation to another. Conclusion For German thyroid specialists, LT4 is the treatment of choice for hypothyroidism. Combination therapy with LT4+LT3 was considered for patients with persistent symptoms. Even in conditions that could affect bioavailability, German thyroid specialists prefer LT4 tablets rather than other LT4 formulations, such as liquid or soft-gel capsules. The widespread use of thyroid hormone for non-hypothyroid conditions is not consistent with current evidence and needs further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928 · cited 1×
“In accordance with current guidelines [13, 35], most responders in the German survey agreed that TH therapy is not indicated in treat mentnaïve euthyroid patients.”
The Incidence and Prevalence of Thyroid Dysfunction in Europe: A Meta-Analysis
Garmendia Madariaga, A., Santos Palacios, S., Guillén-Grima, F., & Galofré, J. C. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2409 · Cited by 800
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 4×
“These data were at least partially in agreement with the 2012 ETA guidelines [13], stating that treat ment with LT4 might be considered in some euthyroid thyroid per oxidase antibody (TPOAb)positive women undergoing fertility treatment, in whom plasma TSH is within the upper normal refer ence range (i.”
BackgroundMethodResultInfluentialLevothyroxine in Women with Thyroid Peroxidase Antibodies before Conception
Dhillon-Smith, R. K., Middleton, L. J., Sunner, K. K., Cheed, V., Baker, K., Farrell-Carver, S., Bender-Atik, R., Agrawal, R., Bhatia, K., Edi-Osagie, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812537 · Cited by 303 · cited 1×
“The rationale being to secure eu thyroidism in case of pregnancy, although LT4 treatment neither promotes conception nor reduces the risk of pregnancy complica tions in such individuals [38, 39].”
BackgroundTaylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300
Selenium in thyroid disorders—essential knowledge for clinicians
Winther, K. H., Rayman, M. P., Bonnema, S. J., & Hegedüs, L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0311-6 · Cited by 288 · cited 1×
“Of note, almost onethird of German thyroid specialists would consider selenium or iodine supplementation in patients with au toimmune thyroiditis, which, however, is not recommended to pa tients with autoimmune thyroiditis according to a recent ETA sur vey on the use of selenium supplementation in Hashimoto’s thy…”
BackgroundSelf-citationAn Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 1×
“Furthermore, combination therapy with LT4 + LT3 or DTE is also gaining attention [17], mostly due to growing demands from patients dissatisfied with the LT4 treatment [20, 21].”
BackgroundWinther, K. H., Cramon, P., Watt, T., Bjorner, J. B., Ekholm, O., Feldt-Rasmussen, U., Groenvold, M., Rasmussen, Å. K., Hegedüs, L., & Bonnema, S. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0156925 · Cited by 152 · cited 2×
“Thyroid guidelines uniformly favor LT4 as standard therapy [12]; however, some patients with thyroid failure have persistent symp toms despite adequate thyroid hormone replacement therapy with LT4 [9].”
BackgroundSelf-citationHoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
Lillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2018) · Thyroid · doi:10.1089/thy.2017.0517 · Cited by 150 · cited 1×
“Side effects, including excess morbidity [22, 23] and mortality [24], due to possible factitious hyperthyroidism are a concern, and the broad evidence for non superiority of combination therapy over LT4 does not support this trend [12].”
BackgroundSelf-citationPrimary hypothyroidism and quality of life
Hegedüs, L., Bianco, A. C., Jonklaas, J., Pearce, S. H., Weetman, A. P., & Perros, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00625-8 · Cited by 144 · cited 1×
“The aforementioned, together with the fact that quality of life is not fully restored [9, 10] in a significant pro portion of patients, is one of several reasons for a continued pur suit to optimize TH substitution in hypothyroid individuals.”
BackgroundSelf-citationLillevang-Johansen, M., Abrahamsen, B., Jørgensen, H. L., Brix, T. H., & Hegedüs, L. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0006 · Cited by 100 · cited 1×
“Side effects, including excess morbidity [22, 23] and mortality [24], due to possible factitious hyperthyroidism are a concern, and the broad evidence for non superiority of combination therapy over LT4 does not support this trend [12].”
BackgroundSelf-citationAbrahamsen, B., Jørgensen, H. L., Laulund, A. S., Nybo, M., Bauer, D. C., Brix, T. H., & Hegedüs, L. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2416 · Cited by 98 · cited 1×
“Side effects, including excess morbidity [22, 23] and mortality [24], due to possible factitious hyperthyroidism are a concern, and the broad evidence for non superiority of combination therapy over LT4 does not support this trend [12].”
BackgroundSelf-citationThvilum, M., Brandt, F., Almind, D., Christensen, K., Brix, T. H., & Hegedüs, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075789 · Cited by 92 · cited 1×
“Although all available LT4 formulations are regarded as effec tive in treating hypothyroidism, preexisting morbidity may be in creased in hypothyroid individuals, and postdiagnosis comorbid ity due to psychiatric [4] and somatic [5] disorders is higher than in euthyroid controls.”
BackgroundSelf-citationStandardized Map of Iodine Status in Europe
Ittermann, T., Albrecht, D., Arohonka, P., Bilek, R., de Castro, J. J., Dahl, L., Filipsson Nystrom, H., Gaberscek, S., Garcia-Fuentes, E., Gheorghiu, M. L., et al. (2020) · Thyroid® · doi:10.1089/thy.2019.0353 · Cited by 92
Self-citationMitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81 · cited 1×
“Furthermore, combination therapy with LT4 + LT3 or DTE is also gaining attention [17], mostly due to growing demands from patients dissatisfied with the LT4 treatment [20, 21].”
BackgroundSelf-citationJonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78
Medici, B. B., Nygaard, B., la Cour, J. L., Grand, M. K., Siersma, V., Nicolaisdottir, D. R., Lind, B., Olivarius, N. D. F., & Andersen, C. L. (2019) · Thyroid® · doi:10.1089/thy.2018.0539 · Cited by 63
Michaelsson, L. F., Medici, B. B., la Cour, J. L., Selmer, C., Røder, M., Perrild, H., Knudsen, N., Faber, J., & Nygaard, B. (2015) · European Thyroid Journal · doi:10.1159/000437262 · Cited by 57 · cited 2×
“This can probably be explained by changing clinical practices, particularly a decreasing thyroid stimulating hormone (TSH) threshold for initiating treatment [17] and increasing the use of biochemical tests [18, 19].”
BackgroundUse of Thyroid Hormones in Hypothyroid and Euthyroid Patients; the 2019 Italian Survey
Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Hegedüs, L. (2020) · European Thyroid Journal · doi:10.1159/000502057 · Cited by 52 · cited 3×
“In contrast, 75 % of respondents in the Italian survey [11] and 74 % in the Romanian survey [33] recommended softgel capsules or liquid solutions to patients on LT4 therapy who have poor bio chemical control of their hypothyroidism.”
BackgroundResultSelf-citationRiis, K. R., Frølich, J. S., Hegedüs, L., Negro, R., Attanasio, R., Nagy, E. V., Papini, E., Perros, P., & Bonnema, S. J. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01555-y · Cited by 37
Self-citationBednarczuk, T., Attanasio, R., Hegedüs, L., Nagy, E. V., Negro, R., Papini, E., Perros, P., & Ruchała, M. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0048 · Cited by 33 · cited 12×
“The results in the German sur vey are in agreement with reports from other countries in the THE SIS survey, where 29.6 % of the Polish [32], 30 % of the Finnish [30], and 56.8 % of the Romanian [33] respondents would prescribe se lenium or iodine supplementation, but a lot higher than in the Dan ish (6.6”
BackgroundResultInfluentialSelf-citationNiculescu, D. (2020) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2020.462 · Cited by 28 · cited 11×
“[37], Spanish (14.1 %), and Bulgarian (15”
ResultInfluential
Cited by
Levothyroxine: conventional and novel drug delivery formulations.
Liu, H., Li, W., Zhang, W., Sun, S., & Chen, C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac030 · Cited by 63
Younes, Y. R., Perros, P., Hegedüs, L., Papini, E., Nagy, E. V., Attanasio, R., Negro, R., & Field, B. C. T. (2023) · Clinical Endocrinology · doi:10.1111/cen.14812 · Cited by 19
“1% response rate with 163 responses.(23) A further limitation of the study is that the views of general practitioners, who successfully manage most hypothyroidism in the (A)”
BackgroundSelf-citationAttanasio, R., Žarković, M., Papini, E., Nagy, E. V., Negro, R., Perros, P., Akarsu, E., Alevizaki, M., Ayvaz, G., Bednarczuk, T., et al. (2024) · Thyroid® · doi:10.1089/thy.2023.0580 · Cited by 18
Self-citationRiis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
Metadata
- Authors
- Vardarli, I., Brandenburg, T., Hegedüs, L., Attanasio, R., Nagy, E., Papini, E., Perros, P., Weidemann, F., Herrmann, K., & Führer, D.
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2022-05-31
- Volume
- 130
- Issue
- 09
- Pages
- 577-586
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W4281629350
- Cited by
- 24
- References
- 23
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.